# 8-Week Atopic Dermatitis (AD) Treatment Study

> **NCT03386032** · PHASE3 · COMPLETED · sponsor: **Procter and Gamble** · enrollment: 65 (actual)

## Conditions studied

- Atopic Dermatitis Eczema

## Interventions

- **DRUG:** Investigational OTC Cream
- **DRUG:** 0.05% Desonide
- **OTHER:** Placebo Cream

## Key facts

- **NCT ID:** NCT03386032
- **Lead sponsor:** Procter and Gamble
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-27
- **Primary completion:** 2018-08-18
- **Final completion:** 2018-08-18
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03386032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03386032, "8-Week Atopic Dermatitis (AD) Treatment Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03386032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*